Eisler Capital (US)’s Cytokinetics CYTK Stock Holding History

Eisler Capital (US)’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,000	Closed	-$1.81M	–	635
2024 Q1	$2.1M	Buy	+30,000	New	+$2.32M	0.05%	275

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eisler Capital (US)'s CYTK Position: Q2 2024 in Review

Eisler Capital (US) sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 30,000 shares — an estimated $1.81M sold.

Eisler Capital (US) first reported a position in CYTK in Q1 2024 and held it in 1 quarter. The position peaked at $2.1M in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

Eisler Capital (US) reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
Eisler Capital (US) sold 30,000 Cytokinetics shares in Q2 2024, an estimated $1.81M.
Eisler Capital (US) first reported a position in Cytokinetics in Q1 2024 and held it in 1 quarter.
Eisler Capital (US)'s Cytokinetics position peaked at $2.1M in Q1 2024.
343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Eisler Capital (US)'s 13F filing for Q2 2024, filed 13 Aug 2024.